R&D and GxP regulated environments have different risk profiles, compliance requirements, and testing constraints. Learn why a single unified pen test scope fails both and how to run dual-scope engagements efficiently.

Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.